Summary

Daptomycin Trends and Forecast
The future of the global daptomycin market looks promising with opportunities in the 300mg and 500mg markets. The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030. The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Daptomycin by Segment
The study includes a forecast for the global daptomycin by indication, age group , strength, and region.

Daptomycin Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
• Complicated Skin Structure Infections
• Bacteremia

Daptomycin Market by Age Group [Shipment Analysis by Value from 2018 to 2030]:
• Pediatric
• Adult

Daptomycin Market by Strength [Shipment Analysis by Value from 2018 to 2030]:
• 300mg
• 500mg

Daptomycin Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Daptomycin Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies daptomycin companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the daptomycin companies profiled in this report include-
• Teva Pharmaceuticals Industries
• Merck
• Cipla
• Pfizer
• BE Pharmaceuticals
• Reddy’S Laboratories
• Mylan
• Fresenius Kabi
• Nichi-Iko Pharmaceutical
• Novo Holdings

Daptomycin Market Insights
Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.
Within this market, 500mg will remain the larger segment due to its efficacy and stability.
North America will remain the largest over the forecast period due to growing several government initiatives.

Features of the Global Daptomycin Market

Market Size Estimates: Daptomycin market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Daptomycin market size by indication, age group , strength, and region in terms of value ($B).
Regional Analysis: Daptomycin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different indication, age group , strength, and regions for the daptomycin market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the daptomycin market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for daptomycin market?
Answer: The global daptomycin market is expected to grow with a CAGR of 4.5% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the daptomycin market?
Answer: The major drivers for this market are increasing population affected by skin and skin structure infections and expanding application as an antibacterial agent, and increasing bloodstream infections, such as sepsis.

Q3. What are the major segments for daptomycin market?
Answer: The future of the daptomycin market looks promising with opportunities in the 300mg and 500mg markets.

Q4. Who are the key daptomycin market companies?
Answer: Some of the key daptomycin companies are as follows:
• Teva Pharmaceuticals Industries
• Merck
• Cipla
• Pfizer
• BE Pharmaceuticals
• Reddy’S Laboratories
• Mylan
• Fresenius Kabi
• Nichi-Iko Pharmaceutical
• Novo Holdings



Q5. Which daptomycin market segment will be the largest in future?
Answer: Lucintel forecasts that complicated skin structure infections will remain the larger segment over the forecast period due to heightened research and development initiatives.

Q6. In daptomycin market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest over the forecast period due to growing several government initiatives.

Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the daptomycin market by indication (complicated skin structure infections and bacteremia), age group (pediatric and adult), strength (300mg and 500mg), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

ページTOPに戻る

Table of Contents